NCT07746440|Completed
Impact of Cannabis Use and Abstinence on Emotion
ICAE
Impact of Cannabis Withdrawal and Early Abstinence on Threat and Reward Processing
Loading search results
ICAE
Impact of Cannabis Withdrawal and Early Abstinence on Threat and Reward Processing
Sponsor study identifier
interventional
30
1 country
1
Study Start
January 24, 2022
Actual (reported)Primary Completion
July 15, 2024
Actual (reported)Study Completion
July 15, 2024
Actual (reported)The goal of this experimental study is to test how three weeks of cannabis abstinence impacts threat and reward processing in females with Cannabis Use Disorder. The main questions it aims to answer are: Compared to using cannabis as usual, will cannabis cue reactivity increase throughout three weeks of abstinence from cannabis? Compared to using cannabis as usual, will threat reactivity be elevated at weeks 1 and 2 of abstinence followed by a decrease at week 3 of abstinence? Compared to using cannabis as usual, will non-drug reward reactivity be lower at weeks 1 and 2 of abstinence followed by an increase at week 3 of abstinence? Compared to successful 3-week abstainers, will threat, non-drug reward, and cannabis cue reactivity differ in relapsers? Researchers will compare females with CUD who abstain from cannabis for three weeks to those who continue to use cannabis as usual to see how cannabis abstinence impacts threat and reward processing. Participants will: Be randomly assigned to continue using cannabis as usual or abstain from cannabis for three weeks Visit the lab 6 times over three weeks, followed by a 1-month follow-up lab visit for the participants assigned to the cannabis abstinence condition Complete phone surveys every other day across the three week study period
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 15, 2024
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 24, 2022
Actual (reported)July 15, 2024
Actual (reported)July 15, 2024
Actual (reported)July 30, 2026
Actual (reported)August 5, 2026
Actual (reported)Late Positive Potential
The Late Positive Potential (neural measure recorded via electroencephalography) will be quantified from \~400 to 3000ms at central-parietal sensors relative to the onset of a cannabis, neutral, unpleasant, or pleasant image. The Late Positive Potential to cannabis vs. neutral and cannabis vs. pleasant will be the primary contrasts of interest.
Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
Reward Positivity
The Reward Positivity (neural measure recorded via electroencephalography) will be quantified from \~200-300ms at frontal-central sensors relative to the onset of monetary win and loss feedback. The win vs. loss contrast will be the primary outcome of interest.
Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
Eyeblink Startle Response
The Eyeblink Startle Response (recorded via EMG sensors) will be quantified as the peak blink amplitude relative to the onset of an auditory startle probe during blocks with predictable shocks, unpredictable shocks, and no threat of shock. The Eyeblink Startle Response during unpredictable shock threat vs. no shock threat will be the primary contrast of interest.
Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
Delta Power
Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
Delta Intertrial Phase Coherence
Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up
Participants randomly assigned to this arm will receive contingency management for three weeks to reinforce sustained abstinence from cannabis and attendance at all lab visits.
Participants randomly assigned to this arm will receive contingency management for three weeks to reinforce attendance at all lab visits. Participants will continue to use cannabis as usual.
Escalating monetary reinforcement is provided for continuous cannabis abstinence and lab visit attendance across the three week study period.
Escalating monetary reinforcement is provided for lab visit attendance across the three week study period.
The BRAINS Lab in the Department of Psychology at Florida State University
Tallahassee, Florida, 32304, United States
30 participants (actual enrollment reported by the registry).
First Submitted
July 30, 2026
First Posted
August 5, 2026
Study Start
January 24, 2022
Actual (reported)Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
July 15, 2024
Actual (reported)Study Completion
July 15, 2024
Actual (reported)Last Updated
August 5, 2026
Record last verified: 2026-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: